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PFSAbstract Aim of the work: To evaluate the prognostic value and accuracy of PET/CT in DLBCL
patients with post-treatment CT-residual masses with concern in overall (OAS) and progression-
free survival (PFS).
Materials and methods: We retrospectively studied 62 patients with DLBCL who had CT docu-
mented residual masses (CRu) after completion of chemotherapy.
Results: Forty-four patients with negative PET scan were free of relapse while 4 out of 18 patients
with positive scan showed CR, the other 14 patients had developed relapse. PET attained a sensi-
tivity of 100%, a speciﬁcity of 91%, a NPV of 100% and a PPV of 77.8% and an accuracy of
93.5%. The median OAS time was 33.59 months in patients with negative scan and 19.00 months
in patients with positive scan with highly signiﬁcant correlation (P value 0.0001) and the median
PFS time was 29.53 months in patients with negative scan versus only 4.00 months in patients with
positive scan with highly signiﬁcant correlation (P value 0.0000).
Conclusion: PET/CTplays helpful part in evaluationof therapy response inDLBCLpatientswithCTresid-
ual mass and post-chemotherapy PET could be used as an accurate and good predictor of OAS and PFS.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most frequent
type of non-Hodgkin’s lymphoma (NHL). Its outcome is
heterogeneous, with some patients being cured but others
not responding to therapy and eventually dying as a result of
the disease (1). Although many patients initially respond to
R-CHOP chemotherapy (rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone), the 5-year overall
survival (OS) rates for patients with DLBCL vary from 45%
to 82% reﬂecting the heterogeneous nature of this disease (2).
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an important noninvasive diagnostic tool for management of
patients with lymphoma and most clinical investigators are
convinced that its use will have an impact on the National
Comprehensive Cancer Network (NCCN) guideline recom-
mendations (3).
PET-CT is the standard imaging modality for staging and
determining remission status at the conclusion of therapy for
the aggressive lymphomas. It is clearly superior to CT alone
when attempting to identify active disease after therapy
completion. In addition, PET-CT has led to the revision of
response criteria, allowing the elimination of the complete
remission/unconﬁrmed category (4).
In the diagnosis of DLBCL, 18-ﬂuorodeoxyglucose posi-
tron emission tomography (18-FDG-PET/CT) has proved to
be highly sensitive in determining sites of disease (3) but the
residual lymph node mass was a commonly encountered diag-
nostic challenge because it is difﬁcult at CT to differentiate
post treatment ﬁbrosis from residual viable malignant changes.
PET/CT has been found useful in the assessment of therapeu-
tic response because of its improved utility in discriminating
benign ﬁbrosis (low-grade or absent FDG uptake) and residual
active lymphoma (elevated FDG uptake) (5).
In the case of patients with PET/CT ﬁndings of residual dis-
ease, a clinical decision is required that may involve continuing
therapy, switching therapy, or consideration of stem cell trans-
plantation. In addition, residual FDG positivity at the end of
therapy is predictive for survival (6).
The aim of this study is: to evaluate the prognostic value
and accuracy of PET/CT in DLBCL patients with post-
treatment CT-residual masses with concern in overall and
progression-free survival (PFS).2. Materials and methods
2.1. Patients
We retrospectively reviewed the records of 85 patients with
pathologically conﬁrmed DLBCL according to WHO classiﬁ-
cation for Tumors of Hematopoietic and Lymphoid Tissue (7).
They were treated and followed up in the Clinical Oncology
Department of the Tanta University Hospital during the per-
iod from April 2010 to October 2013. Twenty-three patients
were excluded from our study because they had received radio-
therapy after chemotherapy because previous analysis of other
population showed that radiation given after chemotherapy
had a signiﬁcant effect on OAS and PFS for patients who
achieved CR after chemotherapy (8) also there was other
exclusion like pregnancy and diabetes.
So, our study included 62 eligible adult patients aged
P18 years and had an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0–2 (9). Staging of lym-
phoma was done according to the Ann Arbor staging system:
Stage I (Involvement of a single lymph node region), Stage II
(Involvement of two or more lymph node regions or lymphatic
structures on the same side of the diaphragm), Stage III
(Involvement of lymph node regions on both sides of the dia-
phragm), Stage IV (Diffuse or disseminated foci of involve-
ment of one or more extralymphatic organs or tissues) (10)
and risk factor evaluation was done according to International
non-Hodgkin’s Lymphoma Prognostic Factors Project (IPI)(11), the risk factors being age greater than 60 years, Stage
III or IV disease, Elevated serum LDH, performance status
of 2, 3, or 4, and more than 1 extranodal site.
All patients had ﬁnished chemotherapy and showed CT
evidence of residual mass >1.5 cm. Written; informed consent
was obtained from all patients before enrollment into the
study.
2.2. Treatment
All patients were treated with six cycles of R-CHOP regimen
[rituximab 375 mg/m2i.v. on day one D1, cyclophosphamide
750 mg/m2i.v. on D1, vincristine 1.4 mg/m2i.v. on D1,
doxorubicin 50 mg/m2i.v. on D1, and prednisone 100 mg p.o.
on D1–5] recycled every 21 days. Complete hematological
work up was done before every cycle. All the investigations
done during the pretreatment period were repeated by the
end of the 3rd cycle and properly assessed. The response to
treatment was assessed according to international workshop
criteria (REF) (12), complete remission (CR) was deﬁned as
disappearance of all evidence of disease. Relapse disease or
progressive disease was deﬁned as any new lesion occurring
or a lymph node/extranodal site with a short axis diameter
of <1.0 cm increasing by P50% and to a size of
1.5 · 1.5 cm or more than 1.5 cm in the long axis and at least
a 50% increase in the longest diameter of any single previously
identiﬁed node/extranodal site >1 cm in its short axis.
2.3. Follow up
Patients were seen weekly during treatment and then monthly
in the ﬁrst year, every 2 months in the second year, every
4–6 months thereafter or at any time if there is any complaint.
Patients were monitored by physical examination, complete
hematological work up, chest X-ray, abdomino-pelvic ultraso-
nography, computed tomography of the neck; chest, abdomen
and pelvis were done at the end of treatment, every 3 months
in the 1st year, every 6 months in 2nd year and annually there-
after and in any time when clinically indicated (12). The follow
up period ranged between 6 months to 36 months with a med-
ian of 14 months. Fourteen patients with progressive disease
(with evidence of relapse) were shifted to salvage therapy.
2.4. Methods
2.4.1. PET/CT
All patients were imaged with dedicated PET-CT scanner
(Siemens, Biograph-2) 6–8 weeks after completion of chemo-
therapy. All patients were fasted for at least 6 h before FDG
injection. Fasting blood glucose level of less than 150 mg/dl
was requirement in all patients. The scan started 60 min after
intravenous administration of 2.516 MBq (0.068 mCi/kg)
FDG, during this period, the patient was instructed to rest
without talking. CT was performed from skull base to pelvis
by performing a scout view followed by a spiral CT with
80 mA, 140 kVp. No oral contrast was given, and water only
was used to delineate bowel. Intravenous 130 ml of iohexol
(Omnipaque 300 mg iodine/ml) was administered. On
completion of CT, 2D PET emission data (4 min per bed
position covering an axial FOV of 15.7 cm with a 3-slice
overlap) was obtained. The total scanning time varied between
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images were reconstructed in trans-axial, coronal and sagittal
planes.
2.5. Image analysis
According to the criteria of the International Harmonization
Project (13), visual assessment was used to categorize
FDG-PET scan ﬁndings as positive or negative. A PET/CT
scan is deﬁned as positive if there is abnormal FDG uptake
greater than background in surrounding tissue and unrelated
to physiologic sites of tracer uptake (e.g. bowel, myocardium),
without a speciﬁc standardized uptake value (SUV) cut-off and
a PET/CT scan is deﬁned as negative if there is no 18F-FDG
uptake. For residual hepatic or splenic lesion, abnormal
uptake was deﬁned as FDG accumulation greater than in the
liver (13).
2.6. Statistical analysis
The data were analyzed using SPSS 13.0 software package.
The correlation of PET/CT negative residual masses and




PS 0 13 27.08 1
1 26 54.17 5
2 9 18.75 8
Sex Female 18 37.50 6
Male 30 62.50 8
Bsymtoms Negative 31 64.58 5
Positive 17 35.42 9
Stage I 18 37.50 1
II 22 45.83 2
III 4 8.33 4
IV 4 8.33 7
Extranodal Negative 40 83.33 14
Positive 8 16.67 0
Size 7 <7 cm 39 81.25 12
>7 cm 9 18.75 2
Bmarrow Normal 46 95.83 8
Hyper 2 4.17 6
LDH Normal 25 52.08 4
High 23 47.92 10
Size of res <2 41 85.42 5
>2 7 14.58 9
Nu of resid 1 35 72.92 4
2 10 20.83 5
3 3 6.25 5
IPI 0 12 25.00 0
1 24 50.00 1
2 9 18.75 5
3 2 4.17 6
4 1 2.08 2
Events of OAS Alive 44 91.67 9
Died 4 8.33 5
ve, negative; +ve, positive; PS, performance state; B marrow, bone ma
residual; IPI, international prognostic index; OAS, overall survival.characteristics was analyzed using Chi-square test. Progres-
sion-free survival was deﬁned as the length of time from remis-
sion to being worse and overall survival was deﬁned as the
length of time from diagnosis to death. The Kaplan–Meier
method and Log-rank test were used to analyze the correlation
of patient survival with PET/CT negative residual masses and
PET/CT positive residual masses; a signiﬁcant level of P value
(0.0001) was used. Sensitivity, speciﬁcity, accuracy, positive
(PPV) and negative predictive values (NPV) of positive and
negative PET scan were calculated.
3. Results
Between April 2010 and October 2013, the total number of
patients eligible for this study was 62. Patient and tumor
characteristics are listed in Table 1. The age ranged from 18
to 73 years and the mean age was 51.146 and 52.357 years in
negative and positive PET/CT patients respectively with no
signiﬁcant differences found between them (P value 0.760).
About 81% of patients with negative PET/CT had PS (0–1)
versus only 42.85% patients with positive scan with
statistically signiﬁcant differences (P value 0.017). About
62% of patients were males. According to stage of disease,CT (+ve) Total Chi-square
% N % X2 P-value
7.14 14 22.58 8.131 0.017
35.71 31 50.00
57.14 17 27.42
42.86 24 38.71 0.131 0.717
57.14 38 61.29
35.71 36 58.06 3.710 0.054
64.29 26 41.94




100.00 54 87.10 4.429 0.035
0.00 8 12.90
85.71 51 82.26 0.154 0.695
14.29 11 17.74
57.14 54 87.10 11.934 0.001
42.86 8 12.90
28.57 29 46.77 2.407 0.121
71.43 33 53.23
35.71 46 74.19 12.678 0.000
64.29 16 25.81
28.57 39 62.90 10.762 0.005
35.71 15 24.19
35.71 8 12.90





64.29 53 85.48 5.578 0.018
35.71 9 14.52
rrow; LDH, lactate dehydrogenase hormone; nu of resid, number of
Table 2 The clinical course and PET ﬁndings in 62 patients
with residual mass.
PET/CT CR Relapse Total
Negative N 44 0 44
% 70.97 0.00 70.97
Positive N 4 14 18
% 6.45 22.58 29.03
Total N 48 14 62
% 77.42 22.58 100.00
Sens. Spec. PPV NPV Accuracy
100.000 91.667 77.778 100.000 93.548
Sens, sensitivity; Spec, speciﬁcity; PPV, positive predictive value;










Fig. 1 Kaplan-Meier plot of overall survival (OAS) curves for (18












Fig. 2 Kaplan-Meier plot of the progression-free survival (PFS) cur
with (44) patients with PET-negative residual masses.
924 D.M. ABO-Sheisha, O.A. Fattahthe majority of negative PET/CT patients were with early
stages (I and II) with highly signiﬁcant difference (P value
0.000).There were no signiﬁcant differences found between
negative PET/CT, positive PET/CT patients and bulky
(P7 cm in diameter) and non bulky disease (P value 0.695).
The majority of patients with negative scan had low risk IPI,
while the remainder had an IPI score of >2 with highly signif-
icant correlation (P value 0.000). Bone marrow involvement
was detected in 42.86% of patients with positive scan com-
pared to only 4.17% of patients with negative scan (P value),
as regards LDH, there was no signiﬁcant difference between
either negative PET/CT or positive PET/CT patients and the













ves for (18) patients with PET-positive residual masses compared
Fig. 3 A female patient aged 55 years with stage I-DLBCL referred for a routine follow up 6 months after completion of her
chemotherapy, no clinical symptoms, post-treatment CT showed splenic lesion. (A) Axial CT scan with contrast shows: a hypodense focal
lesion in the spleen measured 2.5 cm. (B–D) Maximum–intensity projection PET/CT images (axial and coronal ) shows no uptake could be
detected in the lesion (negative PET/CT scan) indicating ﬁbrosis and the patient showed continuous CR in the next follow up.
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single residual site (39 patients), 15 patients had 2 residual sites
and only 8 had 3 residual sites. PET scan was negative in 72%
of patients with single residual mass (P value 0.005).
As regards the clinical course of patients with negative and
positive PET/CT scan, the total 44 patients with negative PET
scan were free of relapse and showed sustained CR during the
follow up period while 4 out of 18 patients with positive scan
showed sustained CR which was considered as false positive
result. The other 14 patients with a positive PET scan had
developed relapse either in the same or outside the residual
site.
In 62 patients with residual masses PET attained a sensitiv-
ity of 100%, a speciﬁcity of 91%, a NPV of 100% and a PPV
of 77.8% and an accuracy of 93.5% in the prediction of relapse
(Table 2).
During follow up period, 53 patients remained alive and the
median OAS of all patients was 31.27 months, the majority
showed negative PET scan with signiﬁcant difference (P value
0.018). In our study, the median OAS time was 33.59 months
in patients with negative scan and 19.00 months in patients
with positive scan with highly signiﬁcant difference (P value
0.0001) Fig. 1, while the median PFS time was 29.53 in patients
with negative scan versus only 4.00 months in patients with
positive scan with highly signiﬁcant difference (P value
0.0000) Figs. 2–5.4. Discussion
The lymphomas are a heterogeneous group of diseases with
respect to their biology, treatment, and prognosis. Despite
the high rate of cure of Hodgkin lymphoma (HL) and diffuse
large B-cell lymphoma (DLBCL), there is a need to alter ther-
apy in patients unlikely to beneﬁt from standard treatment,
while reducing treatment intensity in patients with low risk
disease (14). Positron emission tomography (PET) using
F-18-ﬂuorodeoxyglucose (FDG), integrated with computed
tomography (CT) (PET/CT) has become widely used in the
staging and evaluation of therapy response in lymphomas,
and may provide the means for such an individualized
approach (15).
In this study, we investigated the role of PET/CT scan in 62
patients with DLBCL and showed CT-residual masses after
chemotherapy. The most important result in this study was:
the majority 44 out of 48 patients with negative PET scan were
free of relapse and showed sustained CR during the follow up
period, while 4 out of 18 patients with positive scan showed
sustained CR which was considered as false positive result.
The other 14 patients with a positive PET scan had developed
relapse with follow up in the range of 18 months, either in the
same or outside the residual site. So, in 62 patients with resid-
ual masses PET attained a sensitivity of 100%, a speciﬁcity of
Fig. 4 A female patient aged 27 years with stage II-DLBCL, 1 year after chemotherapy presented clinically by bilateral enlarged 2
cervical lymph nodes, post-treatment CT shows: the right sided lymph node (right arrow) is 1.7 cm and the other one (left arrow) is smaller
in size. (A) Coronal whole body fused PET/CT images showed: active uptake of FDG in the right lymph node with maximum SUV  5.6,
no uptake of the left sided lymph node indicating ﬁbrosis. (B) Axial & (C) Sagittal and (D) Coronal fused PET/CT images show: abnormal
activity of the right sided lymph node.
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93.5% in the prediction of relapse.
Terasawa et al. (16) in 19 studies included 254 patients with
aggressive NHL, they reported ranges for the sensitivity and
speciﬁcity of PET/CT in predicting disease relapse which were
50–70% and 67–100%, respectively. Zijlstra et al. (17) included
15 studies, involving 705 patients, all patients were for post-
treatment evaluation and residual masses, their sensitivity
and speciﬁcity for detection of residual disease in non-
Hodgkin’s lymphoma, were 72% and 100%, respectively, these
results disagree with our study as PET showed high sensitivity
(100%) and speciﬁcity (92%) in prediction of disease recur-
rence but our results agree with Lavely et al. (18) who studied
20 patients with non-Hodking’s lymphoma after completion of
therapy and they found that FDG-PET prediction of relapse
had sensitivity of 100% and a speciﬁcity of 84%. Reske
et al. (19) reviewed 15 other studies on differentiation of viable
lymphoma from scar tissue in 723 patients. Their sensitivity for
detection of active disease and recurrence was 100%.Perhaps the clearest role for the use of PET in lymphoma is
in post-treatment response assessment because of its ability to
distinguish ﬁbrosis or sclerosis from residual active disease.
Many studies have demonstrated a role for post-therapy
FDG-PET imaging in the prediction of aggressive NHL or
HL recurrence (20).
A negative (NPV) (the ability of a negative PET scan to
exclude persistent disease or future relapse) and a positive
predictive value (PPV) (the ability of a positive PET scan to
predict persistent disease or future relapse) of 80 and 100%
were reported for FDG-PET in the identiﬁcation of residual
aggressive NHL after completion of ﬁrst-line chemotherapy
(21).
Juweid et al. (22) found in a retrospective evaluation of 54
patients with aggressive NHL, a PPV of 74% and a NPV of
100% for PET scans. Our results agree with those of Juweid
et al. where our PPV was 78% and NPV was 100%.
We found that, patients with residual mass on CT and hav-
ing a positive PET scan after ﬁnishing chemotherapy for
Fig. 5 A female patient aged 51 years with stage III-DLBCL, 4 months after chemotherapy, post-treatment CT shows: enlarged cervical,
multiple small paraortic, axillary and abdominal lymph nodes. (A) Axial post–contrast CT scan of the neck shows: enlarged left deep
cervical lymph node (black arrow). (B) Axial post-contrast CT scan of the chest shows: small para-aortic and multiple axillary lymph
nodes. (C) Axial post-contrast CT scan of the abdomen shows: multiple enlarged abdominal lymph nodes. (D) & (E) Maximum–intensity
projection PET/CT images (axial and coronal) shows: Bilateral cervical lymph nodes with maximum SUV  4.4, right para-tracheal and
retrocaval lymph nodes with maximum SUV  5.6, multiple bilateral axillary lymph nodes measuring up to 3.5 cm with maximum
SUV  11.7, multiple enlarged abdominal lymph nodes; celiac, porta hepatis, para-aortic, mesenteric, bilateral common iliac, external and
internal iliac as well as bilateral inguinal lymph nodes with maximum SUV  11.6.
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DLBCL patients with a positive PET study in the residual mass
had a poorer prognosis (14/18 recurrences) than patients with a
negative PET study (no recurrence), the results of the
Kaplan–Meier analysis of the progression-free survival (PFS)
were signiﬁcantly different with regard to these two groups
(P value 0.0001). The median follow-up of the patients with
positive PET/CT scan was 52.35 months (range 22 ± 73 months)and the median follow-up of the patients with negative
PET/CT scan was 51.14 months (range 18 ± 70 months).
In terms of response, the 5-year OAS and PFS, Depaja
et al. (23) in his study which included 300 patients with
DLBCL, the rates for patients who achieved CR by PET scan
were signiﬁcantly higher than the rates for those who did not
achieve a CR (i.e., showed relapse (P value 0.0001)). We found
that OAS and PFS were signiﬁcantly poorer in patients with
928 D.M. ABO-Sheisha, O.A. Fattahpositive scan than patients with negative scan, the median PFS
time was 29.53 months in patients with negative scan and only
4.00 months in patients with positive scan with highly signiﬁ-
cant correlation (P value 0.0000).
In the study by Depaja et al. (23), they found that several
known prognostic factors correlate with outcome in patients
with DLBCL, including response to therapy, type of therapy
and IPI score. They stated that any residual disease larger than
2 cm on CT after therapy should be regarded with suspicion
and such masses should be either subjected to biopsy or fol-
lowed closely over time. If residual disease is present at more
than one site, the suspicion for aggressive disease increased.
In our results, we found many factors affecting the result of
PET scan, including stage of the disease, bone marrow involve-
ment, IPI score, performance state, and size of the residual
mass which was more than 1.5 cm (10), there was a signiﬁcant
correlation between these factors and the results of PET scan
(P value 0.005).
This study has some limitations, 1st: it was a retrospective
study, 2nd: small number of patients, 3rd: our treatment
regimen was R-CHOP chemotherapy and other treatment like
radiotherapy was not analyzed.
5. Conclusion
PET/CT plays helpful part in evaluation of therapy response in
DLBCL patients with CT residual mass and post-chemother-
apy PET could be used as an accurate and good predictor of
OAS and PFS.
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